---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-030566"
form_type: "8-K"
ticker: "NUWE"
cik: "0001506492"
company_name: "Nuwellis, Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T19:57:12.858460+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Nuwellis pilots Aquadex with DaVita; issues 1.3M-share warrant to DaVita

## Summary
- Supply and Collaboration Agreement with DaVita to pilot Aquadex ultrafiltration therapy for heart failure in select U.S. markets; pilot expected Q3 2023 through May 2024.
- DaVita receives warrant for 1,289,081 shares at $3.2996/share, vesting in four tranches tied to milestones including pilot extension and revenue achievements.
- DaVita has option to extend agreement for up to 10 years post-pilot; granted registration rights and participation rights in future financings.
- Nuwellis CEO cites DaVita’s clinical infrastructure to accelerate adoption of ultrafiltration therapy.

## SEC filing metadata
- accession: 0001140361-23-030566
- form_type: 8-K
- ticker: NUWE
- cik: 0001506492
- company_name: Nuwellis, Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1506492/000114036123030566/0001140361-23-030566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1506492/000114036123030566/brhc20054628_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-030566
- JSON: https://secwatch.observer/filing/0001140361-23-030566.json
- Plain text: https://secwatch.observer/filing/0001140361-23-030566.txt

## Key facts
- Material Agreements
  Nuwellis, Inc. entered into Common Stock Warrant Agreement with DaVita Inc. valued at warrant to purchase up to an aggregate of 1,289,081 shares of common stock at an exercise price of $ (effective 2023-06-19).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: DaVita Inc.
  - Value: warrant to purchase up to an aggregate of 1,289,081 shares of common stock at an exercise price of $
  - Effective: 2023-06-19
  source text: In conjunction with the Supply Agreement, the Company issued DaVita a warrant to purchase up to an aggregate of 1,289,081 shares of common stock of the Company, par value $0.0001 per share, at an exercise price of $3.2996 per share, provided that at no time can it be exercised for an amount of shares that would represent greater than 19.9% ownership in the Company (the “ Warrant ”) subject to certain vesting milestones.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036123030566/0001140361-23-030566-index.htm
- Material Agreements
  Nuwellis, Inc. entered into Registration Rights Agreement with DaVita Inc. valued at Company agreed to register the resale of the shares of Common Stock issuable upon exercise of the Wa (effective 2023-06-19).
  - Action: entry
  - Agreement: supply
  - Counterparty: DaVita Inc.
  - Value: Company agreed to register the resale of the shares of Common Stock issuable upon exercise of the Wa
  - Effective: 2023-06-19
  source text: Concurrent with the signing of the Supply Agreement and Warrant, the Company entered into a Registration Rights Agreement (“ Registration Rights Agreement ”) with DaVita, whereby the Company agreed, subject to DaVita’s delivery of the Ultrafiltration Services Approval, to register the resale of the shares of Common Stock issuable upon exercise of the Warrant (“ Underlying Shares ”) on a Form S-1 or Form S-3, if eligible, upon DaVita’s demand.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036123030566/0001140361-23-030566-index.htm
- Material Agreements
  Nuwellis, Inc. entered into Supply and Collaboration Agreement with DaVita Inc. valued at DaVita will pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive (effective 2023-06-19).
  - Action: entry
  - Agreement: supply
  - Counterparty: DaVita Inc.
  - Value: DaVita will pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive
  - Effective: 2023-06-19
  source text: On June 19, 2023, Nuwellis, Inc. (the “ Company ”) entered into a Supply and Collaboration Agreement (the “ Supply Agreement ”) with DaVita Inc., a Delaware corporation (“ DaVita ”), pursuant to which DaVita will pilot the Aquadex ultrafiltration therapy system to treat adult patients with congestive heart failure and related conditions within select U.S. markets .
  evidence_url: https://www.sec.gov/Archives/edgar/data/1506492/000114036123030566/0001140361-23-030566-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.